The average person with ALS lives three to five years after diagnosis. That number, while sobering, is an average that masks a wide range of outcomes. About 20% of people live five years or more, roughly 10% survive beyond ten years, and around 5% live twenty years or longer. Several factors influence where someone falls on that spectrum, from the type of ALS they have to their age at onset and the care they receive.
Why “Three to Five Years” Is Only Part of the Picture
The three-to-five-year average starts from the date of diagnosis, but ALS typically takes 10 to 16 months from the first symptom to a confirmed diagnosis. Most people wait three to six months before even seeing a doctor about their initial symptoms, and the diagnostic process itself involves ruling out other conditions. So the total time living with the disease is often longer than the post-diagnosis number suggests.
The wide survival range also matters. Physicist Stephen Hawking famously lived more than 50 years after his diagnosis, an extreme outlier but a reminder that individual trajectories vary enormously. Younger patients, those diagnosed before their mid-40s, tend to progress more slowly. Older age at onset is one of the strongest predictors of a shorter course.
Bulbar Onset vs. Limb Onset
Where ALS first appears in the body has a significant effect on how quickly it progresses. Limb-onset ALS, which starts with weakness in the arms or legs, accounts for roughly two-thirds of cases and generally follows a slower course. Bulbar-onset ALS begins with difficulty speaking or swallowing and tends to progress faster.
The difference becomes especially clear once breathing is affected. Research published in the Journal of Neurology, Neurosurgery & Psychiatry found that once respiratory involvement begins, the monthly mortality rate for people with bulbar-onset ALS is about twice that of limb-onset cases. Bulbar onset is also associated with older age at diagnosis and less frequent use of available medications, both of which compound the shorter survival.
How ALS Progresses Over Time
ALS follows a general pattern, though the speed varies from person to person. Early on, most people notice weakness or clumsiness in one limb, muscle twitching, or changes in speech. These symptoms are often mild enough to be mistaken for other conditions, which contributes to the diagnostic delay.
Over the following months, weakness spreads to other parts of the body. Someone who started with a weak hand may notice their other arm becoming affected, then their legs. Walking becomes difficult, fine motor tasks like buttoning a shirt get harder, and speech may become slurred. Most people eventually need assistance with daily activities like eating, dressing, and bathing.
The late stage centers on breathing. The muscles that control the diaphragm weaken, making it harder to take a full breath, clear mucus, or breathe comfortably during sleep. Respiratory failure is the primary cause of death in ALS, along with cardiovascular complications. This is also where medical interventions can make the biggest difference in extending life.
What Extends Survival
No treatment cures ALS, but several interventions meaningfully affect how long people live with it.
Non-invasive ventilation (a breathing mask, often called BiPAP) is one of the most impactful. A randomized controlled trial published in The Lancet Neurology found that for patients without severe bulbar impairment, BiPAP added a median of about seven months of survival while maintaining quality of life for most of that time. For people with severe bulbar involvement, it helps with sleep-related breathing symptoms but provides less of a survival benefit.
The medication riluzole, the first drug approved for ALS, modestly extends survival. The benefit varies by age group. A real-world study from China found that for patients between 42 and 58 years old, long-term riluzole use extended median survival by about 24 months compared to those who didn’t take it. Other age groups didn’t see a statistically significant difference, which may reflect how the drug interacts with the biology of the disease at different life stages.
For the small percentage of ALS patients (roughly 2%) who carry a specific genetic mutation called SOD1, a newer therapy called tofersen was approved in 2023 under the FDA’s accelerated approval pathway. It works by targeting the underlying genetic cause and was shown to reduce a key biomarker of nerve damage. Confirmatory trials are still underway to verify its long-term clinical benefit.
Beyond medications, multidisciplinary care that includes physical therapy, nutritional support, speech therapy, and respiratory management is associated with better outcomes. Maintaining adequate nutrition is particularly important because ALS increases caloric needs while making eating progressively harder. A feeding tube, when placed at the right time, can help maintain body weight and energy levels.
Factors That Predict a Longer or Shorter Course
A large meta-analysis identified several factors linked to faster progression:
- Older age at symptom onset correlates with shorter survival, though the effect is incremental rather than dramatic.
- Respiratory-onset ALS, a less common subtype where breathing muscles are affected first, carries a higher risk of rapid progression.
- Cognitive changes, particularly a condition called frontotemporal dementia that can co-occur with ALS, nearly triples the risk of earlier death.
- Faster early decline on functional rating scales, meaning the rate at which someone loses abilities in the first months after diagnosis, is one of the strongest predictors of overall trajectory.
On the other end, younger onset, limb-onset disease, slower initial progression, and early use of supportive therapies all favor longer survival. Some people plateau for months or even years at a particular stage before progressing further, though this is difficult to predict in advance.
What Living With ALS Looks Like Over Time
The lived experience of ALS changes substantially as the disease progresses. In the early months, many people continue working and living independently with minor adaptations. As weakness spreads, assistive devices like ankle braces, walkers, and eventually power wheelchairs become part of daily life. Communication devices, ranging from simple letter boards to sophisticated eye-tracking computers, help when speech declines.
The emotional and psychological toll is significant, both for the person with ALS and their caregivers. The mind typically remains sharp even as the body loses function, which creates a unique form of distress. Depression and anxiety are common and treatable, and addressing them can improve quality of life throughout the course of the disease.
Caregiving demands escalate over time. In later stages, most people need 24-hour assistance. Planning ahead for mobility equipment, home modifications, breathing support, and communication tools while they can still participate in those decisions gives people more control over their care and daily life.